Clinical trials: HOMA-IR
Obesity & Overweight, Mobility Disability
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
The primary objective of this study is to assess the effect of enobosarm on total body weight
- Conditions
- Obesity & Overweight, Mobility Disability, HOMA-IR
- Trial name
- PLATEAU (NCT07446998)
- Testing
- Enobosarm, Semaglutide (Wegovy) weekly injection
- Where
- 13 sites in United States
- Volunteers
- 239 people
- Sponsor
- Veru Inc.
End Stage Renal Disease, Continuous Ambulatory Peritoneal Dialysis
Open-label, Randomized Trial to Determine the Effect of Icodextrin Versus Dextrose (Dianeal 2.5%) in HOMA IR
Phase IV post-marketing study to evaluate the effect of Extraneal on the HOMA index in non-diabetic CAPD patients over the long-dwell exchange.
- Trial name
- ECOS (NCT01093547)
- Testing
- Blood samples, Measure of peritoneal ultrafiltrates
- Where
- Colombia
- Sponsor
- Vantive Health LLC
Mild Cognitive Impairment, Metabolic Syndrome
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts…
- Trial name
- NCT03319173
- Testing
- Dietary intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Impaired Glucose Tolerance, Insulin Resistance
Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR
Preliminary research suggests that LIM-0705 improves insulin sensitivity with neutral effects on weight in obese and diabetic rodent models.
- Trial name
- NCT01364155
- Testing
- LIM-0705
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Limerick BioPharma
Diabetes Mellitus, Type 2
Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea
The purpose of this study is investigating the clinical characteristics of newly diagnosed, drug naïve type 2 diabetic patients according to insulin secretion and insulin resistance.
- Trial name
- SURPRISE (NCT01154244)
- Testing
- HOMA-IR
- Where
- 2 sites in South Korea
- Volunteers
- 1,439 people
- Sponsor
- GlaxoSmithKline